EW Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Edwards Lifesciences Corp (EW) does not currently present a strong buying opportunity for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. While the company's revenue growth is notable, the significant decline in net income and EPS, coupled with mixed analyst ratings and lack of strong trading signals, suggests a cautious approach. Holding off on buying until clearer growth trends or positive catalysts emerge would be prudent.
The technical indicators are mixed. The MACD is above 0 but contracting positively, suggesting weakening bullish momentum. RSI is neutral at 51.04, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support is at 79.612, and resistance is at 86.732. The stock is trading near its pivot point, indicating indecision in the market.
Strong Q4 revenue growth of 13.26% YoY, driven by double-digit TAVR momentum. Piper Sandler and Goldman Sachs maintain positive outlooks, with price targets of $100 and $95, respectively.
Net income and EPS dropped significantly (-76.35% and -75.38% YoY, respectively). Analysts have lowered price targets, with UBS, Baird, and Truist maintaining Neutral/Hold ratings. Gross margin slightly declined (-0.96% YoY). Hedge funds and insiders show neutral trading sentiment, and no significant congress trading data is available.
In Q4 2025, revenue increased by 13.26% YoY to $1.57 billion, but net income dropped by 76.35% YoY to $91.2 million. EPS also declined by 75.38% YoY to $0.16. Gross margin fell slightly to 78.15%. This indicates strong top-line growth but significant bottom-line challenges.
Analyst sentiment is mixed. While Piper Sandler and Goldman Sachs maintain Buy/Overweight ratings with price targets of $100 and $95, other firms like UBS, Baird, and Truist have Neutral/Hold ratings and have lowered price targets. The average price target remains slightly above the current price, but valuation concerns persist.
